Rezolute, Inc.
General ticker "RZLT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $429.2M (TTM average)
Rezolute, Inc. follows the US Stock Market performance with the rate: 30.8%.
Estimated limits based on current volatility of 1.1%: low 2.65$, high 2.93$
Factors to consider:
- Total employees count: 59 (+15.7%) as of 2024
- Top business risk factors: Clinical trial delays, Regulatory and compliance, Operational and conduct risks, Supply chain disruptions, Intellectual property risks
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-06-30 to 2027-06-30
- 2025-06-30 to 2026-06-30 estimated range: [2.35$, 5.65$]
- 2026-06-30 to 2027-06-30 estimated range: [1.82$, 4.48$]
Financial Metrics affecting the RZLT estimates:
- Positive: with PPE of -4.4 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -21.51 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: -14.19 < Investing cash flow per share per price, % of -4.53
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term RZLT quotes
Long-term RZLT plot with estimates
Financial data
| YTD | 2023-06-30 | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $55.99MM | $70.42MM | $79.89MM |
| Operating Income | $-55.99MM | $-70.42MM | $-79.89MM |
| Non-Operating Income | $4.20MM | $1.96MM | $5.48MM |
| R&D Expense | $43.81MM | $55.74MM | $61.53MM |
| Income(Loss) | $-51.79MM | $-68.46MM | $-74.41MM |
| Profit(Loss)* | $-51.79MM | $-68.46MM | $-74.41MM |
| Stockholders Equity | $116.17MM | $121.00MM | $162.13MM |
| Assets | $123.72MM | $132.74MM | $175.49MM |
| Operating Cash Flow | $-44.48MM | $-57.37MM | $-69.08MM |
| Capital expenditure | $0.15MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-101.46MM | $48.70MM | $-14.54MM |
| Financing Cash Flow | $11.57MM | $63.03MM | $107.33MM |
| Earnings Per Share** | $-1.01 | $-1.33 | $-0.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.